Demo
Close Language Tab
Locate us
Languages
A
Anuh Pharma Ltd Pharmaceuticals
₹ 99.41 +0.35 (0.35%)
  • NSE
  • BSE

Overview

  • BSE Code 506260
  • NSE Symbol ANUHPHR
  • ISIN Demat INE489G01022
  • Book Value (₹) 32.53
  • Face Value (₹) 5.00
  • Market Cap (₹ Cr.) 946.11
  • P/E (TTM) 20.00
  • EPS (TTM) 4.72
  • Div Yield (%) 0.79

Performance

Today’s Low 98.48
Today’s High 100.00

99.41
52W Low 74.25
52W High 122.85

99.41
Open 98.57
Prev. Close 99.06
Volume 39,145.00

Corporate Actions

Anuh Pharma Limited - Certificate under SEBI (Depositories and Participants) Regulations, 2018
Apr 08, 2025

Anuh Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

About Anuh Pharma Ltd

Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company offers bulk drugs and chemicals. Their products are antibiotics, erythromycin salts, chloramphenicol and other chemicals. The company is part of the SK Group.

Anuh Pharma Ltd was formally created and deployed as a legal entity on February 19, 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs.

The business headquarters of the firm is located in the commercial capital of India, Mumbai. The company is a recognized export house and exports their products to Mexico, Brazil, Iran, Bangladesh, Colombia, Germany, Africa, Singapore and several other countries.

During the year 2006-07, the company commissioned the new plant with all latest modern techniques and facilities. Thus, the production capacity of Antibiotics increased from 400,000 Kg to 600,000 Kg.

During the year 2008-09, the company completed the on-going expansion of their plant, thus they increased the installed capacity by 150 MT per annum. In September 2008, they broadened its footprint unit started commercial production.

In January 2010, the company received approval for their product Erythromycin E.P. from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Erythromycin E.P. in European counties for their own consumption.

In April 2010, the company received approval for their product Pyrazinamide from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Pyrazinamide in European countries for their own consumption.

In June 2010, the company received approval for their product Clobetasol Propionate from European Directorate for the Quality Medicines & Healthcare. This approval paves the way for the company to sell Clobetasol Propionate in European counties for their own consumption.

Founded: 1960
Chairman: Arun L Todarwal
Managing Director: Ritesh B Shah
Address: 3-A Shivsagar Estate, North Wing Dr A B Road Worli, Mumbai, Maharashtra, 400018,
HO Tel: 91-022-6622 7575